Verispan acquired by data rival SDI

Share this article:
Verispan has been bought by rival healthcare analytics firm SDI for an undisclosed price.

A privately owned firm based in Plymouth Meeting, PA, SDI offers similar patient-level data analytics services, but where Verispan's syndicated offerings have formed the crux of its business, SDI has focused more on custom programs. 

SDI's John Ross, VP client services, said the company anticipates minimal redundancies initially. “The services of both firms are pretty complementary,” he said. “The only overlap is in the patient level data space, and within that, only on the custom offerings. That's one of the aspects of the deal that made it very attractive for both parties.”

The organization will be known as SDI, though select offerings may retain the Verispan brand, Ross said. It will boast a staff of 700, with Verispan's 500 employees remaining in their Yardley, PA, offices, and will be led by CEO Andrew Kress, who was president of SDI. Verispan CEO Wayne Yetter is leaving the company after a transition period. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.